Vaccitech’s Immunotherapy Combo With Opdivo Shows Hepatitis B Promise
Searching For A Functional Cure
The UK company did not profit greatly from its role in COVID-19 vaccine, Vaxzevria, but hopes the same technology can form part of a breakthrough in hepatitis B.
You may also be interested in...
Bepirovirsen made the hepatitis B virus undetectable in nearly 30% of patients in a Phase II study – but it remains to be seen whether this response be sustained once treatment with the novel antisense product ends.
The University of Oxford spin-out is backing its academic partners to succeed against COVID-19 – but must also look to its own commercial future using the same adenovirus platform.
The UK biotech looks to have reached the end of the road, despite some encouraging signs from its microbiome-based pipeline.